SCHEMBL4025941

SCHEMBL4025941

Clc1ccc(-c2[nH]c(C3CCN(CCCc4ccccc4)CC3)nc2-c2ccncc2)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.47
DRD4 P21917 5/20 0.47
DRD3 P35462 3/20 0.47
MAPK11 Q15759 4/20 0.45
MAPK14 Q16539 4/20 0.45
MAPK13 O15264 3/20 0.45
RAF1 P04049 3/20 0.45
MAPK12 P53778 3/20 0.45
SIGMAR1 Q99720 3/20 0.45
PRCP P42785 1/20 0.45
BRAF P15056 1/20 0.44
MAPK9 P45984 2/20 0.42
SOAT1 P35610 1/20 0.42
AKT1 P31749 1/20 0.42
AKT2 P31751 1/20 0.42
AKT3 Q9Y243 1/20 0.42
CSNK1A1 P48729 1/20 0.41
CSNK1D P48730 1/20 0.41
RPS6KA3 P51812 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4026457 0.95 DRD4 (0.51) DRD2DRD4DRD3MAPK11MAPK14
SCHEMBL4027146 0.90 AKT1 (0.49) DRD2DRD4DRD3MAPK11MAPK14
SCHEMBL13810833 0.90 BRAF (0.47) DRD2DRD4DRD3MAPK11MAPK14
SCHEMBL7744430 0.86 BRAF (0.43) MAPK11MAPK14MAPK13RAF1MAPK12
SCHEMBL4031401 0.84 BRAF (0.43) DRD2DRD4DRD3MAPK11MAPK14
SCHEMBL4025420 0.84 BRAF (0.43) MAPK11MAPK14MAPK13RAF1MAPK12
SCHEMBL4024657 0.84 BRAF (0.43) DRD2DRD4DRD3MAPK11MAPK14
SCHEMBL4025250 0.84 BRAF (0.43) DRD2DRD4DRD3MAPK11MAPK14
SCHEMBL4028496 0.82 NPC1 (0.46) MAPK11MAPK14MAPK13RAF1MAPK12
SCHEMBL13810887 0.82 BRAF (0.47) DRD2DRD4DRD3MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP claimed
EP-0906099-A4 A METHOD OF TREATING CANCER MERCK & CO INC (US) 2001-02-07 EP claimed
EP-0906099-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 1999-04-07 EP claimed
WO-1997036587-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-10-09 WO claimed
EP-0906099-A4 A METHOD OF TREATING CANCER MERCK & CO INC (US) 2001-02-07 EP disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 US disclosed
EP-0934270-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 1999-08-11 EP disclosed
EP-0906099-A1 A METHOD OF TREATING CANCER Merck & Co., Inc. (US) 1999-04-07 EP disclosed
US-5717100-A Substituted imidazoles having anti-cancer and cytokine inhibitory activity MERCK & CO., INC. (US) 1998-02-10 US disclosed
WO-1997045412-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-12-04 WO disclosed
WO-1997036587-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1997-10-09 WO disclosed